14208-83-4

Usage

Uses

Used in Pharmaceutical Industry:
3-Amino-isonicotinic Acid Ethyl Ester is used as a reagent for the synthesis of heteroaryl compounds that act as PDE-10 inhibitors. These inhibitors are crucial in the treatment and prevention of central nervous system (CNS), metabolic, and other diseases, as they help regulate the activity of phosphodiesterase enzymes, which play a significant role in these conditions.
Additionally, 3-Amino-isonicotinic Acid Ethyl Ester is employed in the design and evaluation of 1,7-naphthyridones, which are novel KDM5 inhibitors. KDM5 inhibitors have potential applications in the treatment of various cancers by targeting the epigenetic regulation of gene expression, thus providing a promising avenue for cancer therapy.

InChI:InChI=1/C8H10N2O2/c1-2-12-8(11)6-3-4-10-5-7(6)9/h3-5H,2,9H2,1H3

Upstream product

• 64-17-5 ethanol 
• 7579-20-6 3-Aminopyridine-4-carboxylic acid 
• 490-11-9 3,4-pyridinecarboxylic acid 
• 4664-01-1 3,4-pyridinedicarboximide 

Downstream Products

• 64189-08-8 3-Aminopyridin-4-carboxysaeurehydrazid 
• 157361-40-5 ethyl 3-allylaminopyridine-4-carboxylate 
• 152398-05-5 (3-amino-pyridin-4-yl)methanol 
• 372951-30-9 ethyl 3-amido-(N-[3-phenoxy]phenylacetyl)isonicotinate 
• 55279-29-3 3-amino-pyridine-4-carbaldehyde 
• 1093759-41-1 ethyl 3-amino-2-chloroisonicotinate 
• 343-72-6 ethyl 3-fluoroisonicotinate 
• 862314-10-1 ethyl 5-amino-2-chloroisonicotinate 
• 1461601-04-6 3-[(3-phenylpropanoyl)amino]-4-pyridinecarboxylic acid 
• 1461601-05-7 3-[(phenylcarbonyl)amino]-4-pyridinecarboxylic acid 
• 1461603-03-1 ethyl 3-[(phenylcarbonyl)amino]-4-pyridinecarboxylate 
• 16081-85-9 2-phenylpyrido[3,4-d]pyrimidin-4(3H)-one 
• 1461602-98-1 ethyl 3-{[(4-chlorophenyl)acetyl]amino}-4-pyridinecarboxylate 
• 1461603-23-5 ethyl 3-[(3-phenylpropyl)amino]-4-pyridinecarboxylate 

Relevant academic research and scientific papers

TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS

Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X11 and X22 are independently C or N, provided that zero or one of X11 and X22 is N; Ring A represented by the structure is: or; and Q, R11, R22, R33, R44, R66, and p are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes

AROMATIC SULFONE COMPOUND AS ALDOSTERONE RECEPTOR MODULATOR

The present invention provides a compound represented by the following formula (I): [wherein, A represents a group of the following formula (A-1): etc., R1 and R2 each independently represent a hydrogen atom etc., Z represents CR3 etc., W represents CR4 etc., Q represents CR5 etc., R3, R4 and R5 each independently represent a hydrogen atom etc., Y represents an oxygen atom or sulfur atom, X represents an oxygen atom etc. and B represents an optionally substituted aryl group or optionally substituted heteroaryl group], the prodrug thereof or the pharmaceutically acceptable salt thereof for preventing or treating various diseases such as hypertesion, cerebral stroke, cardiac failure, etc.

Synthesis and SAR of 5-, 6-, 7- and 8-aza analogues of 3-aryl-4-hydroxyquinolin-2(1H)-one as NMDA/glycine site antagonists

A series of 5-, 6-, 7- and 8-aza analogues of 3-aryl-4-hydroxyquinolin-2(1H)-one was synthesized and assayed as NMDA/glycine receptor antagonists. The in vitro potency of these antagonists was determined by displacement of the glycine site radioligand [3H]5,7-dicholorokynurenic acid ([3H]DCKA) in rat brain cortical membranes. Selected compounds were also tested for functional antagonism using electrophysiological assays in Xenopus oocytes expressing cloned NMDA receptor (NR) 1A/2C subunits. Among the 5-, 6-, 7-, and 8-aza-3-aryl-4-hydroxyquinoline-2(1H)-ones investigated, 5-aza-7-chloro-4-hydroxy-3-(3-phenoxyphenyl)quinolin-2-(1H)-one (13i) is the most potent antagonist, having an IC50 value of 110 nM in [3H]DCKA binding and a Kb of 11 nM in the electrophysiology assay. Compound 13i is also an active anticonvulsant when administered systemically in the mouse maximum electroshock-induced seizure test (ED50 = 2.3 mg/kg, IP).

Angiotensin II receptor antagonists

Compounds are disclosed having the formula: STR1 The compounds of the invention are angiotensin II receptor antagonists.

Synthesis of Some Benzonaphthyridines and Benzonaphthyridines

Pfitzinger (1-benzylpiperidin-4-one with 7-methylisatin) and Friedlaender (3-aminopyridine-4-carbaldehyde with 2-methylcyclohexanone) syntheses, respectively, were used to prepare the title "azaacridines" containing a methyl substituent peri to the centra

2-(Alkylamino)nicotinic Acid and Analogs. Potent Angiotensin II Antagonists

A series of pyridines and other six-membered ring heterocycles connected to a biphenyltetrazole with a-CH2-NR'-link (1) were discovered to be potent angiotensin II antagonists.In the pyrimidine carboxylic acid series (W = CR, X = N, Y = CH, Z = COOH), compounds with an alkyl group (R') on the exocyclic nitrogen were much more potent than compounds with an alkyl group (R) on the heterocyclic ring.The corresponding pyridine, pyridazine, pyrazine, and 1,2,4-triazine carboxylic acids also showed potent in vitro angiotensin II antagonism.The pyridine (W, X, Y = CH, Z = COOH, R' = n-C3H7) demonstrated potent in vitro activity (pA2 = 10.10, rabbit aorta, and Ki = 0.61 nM, receptor binding in rat liver) as well as exceptional oral antihypertensive activity and bioavailability.Any nonacidic replacement for the carboxylic acid was detrimental for activity.

The ortho effect in pyridines. Part XI(1). Substituent effects on basicity of 2- and 4-substituted 3-aminopyridines

The substituent effects on the pKa values corresponding to the first protonation site of thirty 2- and 4-substituted 3-aminopyridines have been studied.It was found that the relative localized and delocalized effects are apparently sensitive to the variation of substituent position in the pyridine ring.An interaction of the 2-substituent with the protonation centre has mainly inductive character, whereas, the pKa values of 4-substituted 3-aminopyridines are highly affected by through-resonance.The steric effect was found to be insignificant.Keywords: substituent effects / 2- and 4-substituted 3-aminopyridines / basicity